{
    "clinical_study": {
        "@rank": "85646", 
        "arm_group": [
            {
                "arm_group_label": "Ranolazine 1500mg", 
                "arm_group_type": "Experimental", 
                "description": "Ranolazine"
            }, 
            {
                "arm_group_label": "Dofetilide 500mcg", 
                "arm_group_type": "Experimental", 
                "description": "Dofetilide"
            }, 
            {
                "arm_group_label": "Verapamil HCl 120 mg", 
                "arm_group_type": "Experimental", 
                "description": "Verapamil"
            }, 
            {
                "arm_group_label": "Quinidine sulfate 400mg", 
                "arm_group_type": "Experimental", 
                "description": "Quinidine sulfate"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study seeks to compare 4 known QT prolonging drugs versus placebo to determine their\n      effects on electrophysiological and other clinical parameters. The underlying purpose is to\n      determine if depolarization and repolarization effects caused by drugs with differing ionic\n      channel mechanisms can be distinguished from one another, and to gauge the sensitivity and\n      specificity of novel signal analyses for detection of depolarization and repolarization\n      changes. Secondarily,  to evaluate the exposure response relationship and drug induced\n      effects on the heart rate biomarker relationship."
        }, 
        "brief_title": "Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Drug-induced Surface ECG Changes", 
        "detailed_description": {
            "textblock": "This will be a randomized, double blind, 5 way crossover research study in healthy male and\n      female subjects, 18 to 35 years of age, to compare 4 known QT prolonging drugs versus\n      placebo to determine their effects on electrophysiological and other clinical parameters. To\n      maintain the study blind, subjects will be blindfolded during study drug administration. The\n      cardiologists at the central ECG laboratory (Spaulding Clinical Research, LLC) will be\n      blinded to treatment, time, and study day/subject identifiers.\n\n      Subjects who meet all of the following inclusion criteria will be eligible to participate in\n      the study:\n\n        1. Subject signs an Institutional Review Board (IRB) approved written informed consent and\n           privacy language as per national regulations (e.g., Health Insurance Portability and\n           Accountability Act [HIPAA] authorization for sites in the United States) before any\n           study related procedures are performed.\n\n        2. Subject is a healthy man or woman, 18 to 35 years of age, inclusive, who weighs at\n           least 50 kg (110 pounds) and has a body mass index of 18 to 27 kg/m2, inclusive, at\n           Screening.\n\n        3. Subject has normal medical history findings, clinical laboratory results, vital sign\n           measurements, 12 lead ECG results, and physical examination findings at Screening or,\n           if abnormal, the abnormality is not considered clinically significant (as determined\n           and documented by the investigator or designee).\n\n        4. Female subjects must be at least 2 years postmenopausal, surgically sterile or\n           practicing 2 highly effective methods of birth control (as determined by the\n           investigator or designee; one of the methods must be a barrier technique), and not\n           pregnant or lactating before enrollment in the study.\n\n        5. Male or female subjects must agree to practice 2 highly effective methods of birth\n           control (as determined by the investigator or designee; one of the methods must be a\n           barrier technique) from Screening until 30 days after the last dose of study drug.\n\n        6. Subject is highly likely (as determined by the investigator) to comply with the\n           protocol-defined procedures and to complete the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: Subjects who meet all of the following inclusion criteria will be\n        eligible to participate in the study:\n\n          1. Subject signs an IRB approved written informed consent and privacy language as per\n             national regulations (e.g., Health Insurance Portability and Accountability Act\n             [HIPAA] authorization for sites in the United States) before any study related\n             procedures are performed.\n\n          2. Subject is a healthy man or woman, 18 to 35 years of age, inclusive, who weighs at\n             least 50 kg (110 pounds) and has a body mass index of 18 to 27 kg/m2, inclusive, at\n             Screening.\n\n          3. Subject has normal medical history findings, clinical laboratory results, vital sign\n             measurements, 12 lead electrocardiogram (ECG) results, and physical examination\n             findings at Screening or, if abnormal, the abnormality is not considered clinically\n             significant (as determined and documented by the investigator or designee).\n\n          4. Female subjects must be at least 2 years postmenopausal, surgically sterile or\n             practicing 2 highly effective methods of birth control (as determined by the\n             investigator or designee; one of the methods must be a barrier technique), and not\n             pregnant or lactating before enrollment in the study.\n\n          5. Male or female subjects must agree to practice 2 highly effective methods of birth\n             control (as determined by the investigator or designee; one of the methods must be a\n             barrier technique) from Screening until 30 days after the last dose of study drug.\n\n          6. Subject is highly likely (as determined by the investigator) to comply with the\n             protocol defined procedures and to complete the study.\n\n        Exclusion Criteria:\n\n          -  Subjects who meet any of the following exclusion criteria will not be eligible to\n             participate in the study:\n\n               1. Subject has a 12 lead safety ECG result at Screening or Check in of Period 1\n                  with evidence of any of the following abnormalities:\n\n                    -  QTc using Fridericia correction (QTcF) >450 milliseconds (ms) for men and\n                       >470 ms for women\n\n                    -  PR interval >220 ms\n\n                    -  QRS duration >110 ms\n\n                    -  Second- or third-degree atrioventricular block\n\n                    -  Complete left or right bundle branch block or incomplete right bundle\n                       branch block\n\n                    -  Heart rate <40 or >90 beats per minute\n\n                    -  Pathological Q-waves (defined as Q wave >40 ms)\n\n                    -  Ventricular pre-excitation\n\n               2. Subject has more than 12 to 20 ectopic beats during the 3 hour Holter ECG at\n                  Screening.\n\n               3. Subject has a history of unexplained syncope, structural heart disease, long QT\n                  syndrome, heart failure, myocardial infarction, angina, unexplained cardiac\n                  arrhythmia, torsades de pointes, ventricular tachycardia, or placement of a\n                  pacemaker or implantable defibrillator. Subjects will also be excluded if there\n                  is a family history of long QT syndrome (genetically proven or suggested by\n                  sudden death of a close relative due to cardiac causes at a young age) or\n                  Brugada syndrome.\n\n               4. Subject has a history or current evidence of any clinically significant (as\n                  determined by the investigator) cardiovascular, dermatologic, endocrine,\n                  gastrointestinal, hematologic, hepatic, immunologic, metabolic, neurologic,\n                  psychiatric, pulmonary, renal, urologic, and/or other major disease or\n                  malignancy (excluding nonmelanoma skin cancer). The investigator may allow\n                  exceptions to these criteria (e.g., stable mild joint disease [that will not\n                  interfere with or influence the leg raises/exercises required by the protocol,\n                  in the opinion of the investigator], cholecystectomy, childhood asthma)\n                  following discussion with the medical monitor.\n\n               5. Subject has a history of thoracic surgery.\n\n               6. Subject has any condition possibly affecting study drug absorption (e.g.,\n                  gastrectomy, Crohn's disease, irritable bowel syndrome).\n\n               7. Subject has a skin condition likely to compromise ECG electrode placement.\n\n               8. Subject is a female with breast implants.\n\n               9. Subject's laboratory test results at Screening or Check in of Period 1 are\n                  outside the reference ranges provided by the clinical laboratory and considered\n                  clinically significant (as determined and documented by the investigator or\n                  designee).\n\n              10. Subject's laboratory test results at Screening or Check in of Period 1 indicate\n                  hypokalemia, hypocalcemia, or hypomagnesemia according to lower limits of the\n                  reference ranges provided by the clinical laboratory.\n\n              11. Subject's laboratory test results at Screening or Check in of Period 1 are >2 \u00d7\n                  the upper limit of normal (ULN) for alanine aminotransferase or aspartate\n                  aminotransferase, >1.5 \u00d7 ULN for bilirubin, or >1.5 \u00d7 ULN for creatinine.\n\n              12. Subject has a positive test result at Screening for human immunodeficiency virus\n                  antibody, hepatitis C antibodies, or hepatitis B surface antigen.\n\n              13. Subject has a mean systolic blood pressure <90 or >140 mmHg or a mean diastolic\n                  blood pressure <50 or >90 mmHg at either Screening or Check in of Period 1.\n                  Blood pressure will be measured in triplicate after the subject has been resting\n                  in a supine position for a minimum of 5 minutes.\n\n              14. Subject has a known hypersensitivity to ranolazine, dofetilide, verapamil, or\n                  quinidine or related compounds.\n\n              15. Subject has consumed alcohol, xanthine containing products (e.g., tea, coffee,\n                  chocolate, cola), caffeine, grapefruit, or grapefruit juice within 48 hours\n                  before dosing or anticipates an inability to abstain from these products\n                  throughout the duration of the study.\n\n              16. Subject has used nicotine containing products (e.g., cigarettes, cigars, chewing\n                  tobacco, snuff) within 6 weeks before Screening (self reported).\n\n              17. Subject is unable to tolerate a controlled, quiet study conduct environment,\n                  including avoidance of music, television, movies, games, and activities that may\n                  cause excitement, emotional tension, or arousal during the prespecified time\n                  points (e.g., before and during ECG extraction windows).\n\n              18. Subject is unwilling to comply with study rules, including the study specific\n                  diet, attempting to void at specified times (e.g., before ECG extraction\n                  windows), remaining quiet, awake, undistracted, motionless, and supine during\n                  specified times, and avoiding vigorous exercise as directed.\n\n              19. Subject has a history of consuming more than 14 units of alcoholic beverages per\n                  week within 6 months before Screening, has a history of alcoholism or\n                  drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12\n                  ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor), or has a\n                  positive test result for alcohol or drugs of abuse (amphetamines, barbiturates,\n                  benzodiazepines, cannabinoids, cocaine, and opiates) at Screening or Check in of\n                  each period.\n\n              20. Subject has used any prescription or nonprescription drugs within 14 days or 5\n                  half lives (whichever is longer), or complementary and alternative medicines\n                  within 28 days before the first dose of study drug (excluding oral\n                  contraceptives, hormone replacement therapy, aspirin, ibuprofen, and\n                  acetaminophen).\n\n              21. Subject is currently participating in another clinical study of an\n                  investigational drug or has been treated with any investigational drug within 30\n                  days or 5 half lives (whichever is longer) of the compound.\n\n              22. Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or\n                  more, or received a transfusion of any blood or blood products within 60 days,\n                  or donated plasma within 7 days before Check in of Period 1.\n\n              23. Subject has any other condition that precludes his or her participation in the\n                  study (as determined by the investigator)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01873950", 
            "org_study_id": "13-011D", 
            "secondary_id": "SCR-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ranolazine 1500mg", 
                "intervention_name": "Ranolazine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dofetilide 500mcg", 
                "intervention_name": "Dofetilide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Verapamil HCl 120 mg", 
                "intervention_name": "Verapamil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Quinidine sulfate 400mg", 
                "intervention_name": "Quinidine sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Verapamil", 
                "Dofetilide", 
                "Quinidine", 
                "Quinidine gluconate", 
                "Ranolazine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 5, 2013", 
        "number_of_arms": "5", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled Single-Dose, Five Period Crossover Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Spaulding Clinical Research", 
            "last_name": "Carlos Sanabria, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compute maximum mean placebo, and baseline-adjusted change for: PR (ms), QRS (ms), J-Tpeak (ms), Tpeak-Tend (ms), QTc (ms), spatial QRS-T angle (degrees) and ventricular gradient (mVms).", 
            "measure": "Placebo, and baseline-adjusted changes in PR, QRS, J-Tpeak, Tpeak-Tend, QTc, spatial QRS-T angle and ventricular gradient", 
            "safety_issue": "Yes", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01873950"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Different post-dose timepoints employ different techniques for altering heart rate (leg raises and postural maneuvers). Using this data a model for different ECG parameters (same as for primary analysis) and heart rate will be developed. The model will either be a linear or non-linear model (as determined by visual inspection), but the model will be the same for all subjects and maneuvers. The model coefficients for different maneuvers and drugs will be compared.", 
                "measure": "Change in relationship between heart rate and PR, QRS, J-Tpeak, Tpeak-Tend, QTc, spatial QRS-T angle and ventricular gradient", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).\nThe magnitude of change (mean and 90% CI) in QTc for the observed mean Cmax for each drug, highest individual concentration observed with the dose, and other appropriate concentrations pertaining to drug may be calculated.", 
                "measure": "Change in PR, QRS, J-Tpeak, Tpeak-Tend, QTc, spatial QRS-T angle and ventricular gradient using Exposure/Response", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "Food and Drug Administration (FDA)", 
        "sponsors": {
            "collaborator": {
                "agency": "Spaulding Clinical Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Food and Drug Administration (FDA)", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}